poor compliance of patients. Accumulating evidence has demonstrated that osteoporosis patients have an imbalance of osteoblast differentiation and osteoclast production. 11 Thus, a better understanding of the pathophysiological roles of osteoblasts and osteoclasts in bone formation and resorption is required.
Melatonin, discovered by Aaron Lerner in 1958, 12 is an avirulent indoleamine that modulates circadian rhythms and has a wealth of other beneficial effects. 13, 14 In mammals, it is mainly secreted by the pineal gland during darkness, 15 and exposure to light at night may decrease plasma melatonin levels. 16 Apart from the pineal gland, studies have suggested that melatonin may be synthesized locally in the bone marrow as well as in many other tissues. 17, 18 Melatonin synthesized in the bone marrow can accumulate at concentrations twice that of nocturnal blood levels, 17, 19, 20 which may produce strong local effects on bone. Osteocytes exhibit a 24 hours cycle that is influenced by age, gender, diseases, and hormonal status. [21] [22] [23] Melatonin, secreted from the pineal gland, may serve as a circadian clock in all peripheral tissues, including bone, where it keeps bone metabolism in synchrony with the diurnal cycle and maintains homeostasis of the bone microenvironment. We previously reviewed the roles of melatonin in cancer, [24] [25] [26] ischemic heart diseases, 27, 28 fibrosis, 29 and sepsis. 30 Previous reviews have suggested that melatonin plays a pivotal role in bone. 31, 32 Recent studies have demonstrated that melatonin can protect against osteoporosis 33 and maintain homeostasis of bone metabolism. 34, 35 In light of the emerging roles of melatonin in bone metabolism, the present review discusses recent breakthroughs related to melatonin in osteoporosis ( Figure 1 ). Based on published data, we hypothesize that melatonin is a potential drug candidate against osteoporosis. In the present review, we initially introduce information related to melatonin and bone metabolism, as well as the association between melatonin and osteoporosis. Second, we summarize the mechanisms of melatonin in modulating bone metabolism and the antiosteoporotic actions of melatonin in diverse models, ranging from cells to human beings. Finally, we discuss the effects of melatonin on osteoporosis-related diseases and provide potential directions. This review summarizes the role of melatonin in bone metabolism and formation, which may be helpful for the clinical therapy of osteoporosis.
| MECHANISMS UNDERLYING

MELATONIN'S ACTION ON OSTEOPOROSIS
| Melatonin maintains metabolic homeostasis in bone
Aging 36 is the result of biological events that progressively and irreversibly compromise the function of vital organs. The related pathophysiological changes include cancer, [37] [38] [39] cardiovascular diseases, [40] [41] [42] neurological diseases, [43] [44] [45] metabolic syndrome, [46] [47] [48] and motor system diseases. 20 Osteoporosis is a debilitating chronic bone disease accompanied by increased bone loss and a high risk of fracture and is F I G U R E 1 Signaling network of osteogenesis and osteolysis. This illustration identifies the signaling network involved in bone formation and resorption. Normal bone remodeling depends on the balance between bone-forming osteoblasts and bone-resorbing osteoclasts. Osteoblasts are the primary driver and may modulate the activity of osteoclasts via RANKL. Five main signaling pathways, including TGF-β, BMP2, Wnt, melatonin, and ITAM, are involved in the regulation of osteoblasts. These networks promote downstream osteogenetic molecules (eg, ALP, BMP2, and osteoprotegerin) and osteolysis molecules (TNF-α, ROS, IL-1β, IL-6) the most common reason for fracture among the elderly. [49] [50] [51] [52] [53] [54] Currently, numerous drugs have been produced to treat osteoporosis by inhibiting bone resorption, although they offer few benefits to bone formation and fail to reverse bone loss. 55 Moreover , conventional therapies have their own adverse effects, such as osteonecrosis,  56 atrial fibrillation,  57 esophageal cancer, 58 eczema, 59 cellulitis, 60 deep venous thrombosis, 33 and osteosarcoma, 61 all of which may contribute to a lack of compliance. Therefore, it is essential to find new drugs or endogenous substances to treat osteoporosis. Melatonin is a chronobiotic derived from the pineal gland, which modulates circadian rhythms and participates in a wide range of physiological processes. 62, 63 In 1917, McCord et al 64 reported an interesting phenomenon that feeding macerated bovine pineal tissue to tadpoles lightened their skin. This pineal factor was isolated from the bovine pineal gland in 1958 and identified as melatonin (N-acetyl-5-methoxytryptamine). 65 Melatonin is common to almost all animals, plants, bacteria, and fungi. 24 Notably, melatonin has no toxicity at any dose. Activation of two well-characterized G-protein-coupled seven-transmembrane-domain receptors (MT1 and MT2) regulates downstream intracellular signaling and exhibits specific biological effects. 66, 67 Additionally, melatonin has receptor-independent actions. Several insightful reviews have provided a comprehensive introduction of melatonin. [68] [69] [70] [71] Several studies have recently demonstrated the beneficial effects of melatonin on bone metabolism, including anabolic actions 34 and anti-resorptive effects. 72 Feskanich et al 73 
| Melatonin promotes osteogenesis in osteoblasts
Melatonin may prevent bone degradation and promote bone formation through mechanisms involving both melatonin receptor-mediated and receptor-independent actions. There are three principal mechanisms of melatonin's effects on bone metabolism: (a) promoting osteoblast differentiation and activity; (b) inhibiting osteoclast differentiation 74 ; (c) scavenging free radicals to resist osteoporosis ( Figure 1 ). Kim et al investigated whether combined fluid shear stress (FSS) and melatonin stimulate signal transduction in cilia-less MC3T3-E1 preosteoclasts. They found that the combination of FSS and melatonin enhances ERK/Akt/mTOR signaling in preosteoclasts, which activates the anabolic effect for the preservation of cell structure and function against osteoporosis. 75 Melatonin upregulates the expression of neuropeptide Y (NPY) and NPY receptor Y1 (NPY1R) and promotes the proliferation and migration of mesenchymal stem cells (MSC). However, melatonin-induced osteoblast differentiation of MSC was suppressed by BIBP3226 (an inhibitor of NPY1R), as evidenced by decreased levels of alkaline phosphatase (ALP), collagen type I α1 chain, osteocalcin, and runt-related transcription factor 2. This result suggests that melatonin promotes osteoblast differentiation of MSC via NPY/NPY1R signaling. 76 Preconditioning of melatonin predominantly reduces the expression of Bax but increases the expression of Bcl2 in bone marrow-derived MSC (BMSC).
In addition, melatonin promotes osteogenesis through increasing osteocalcin expression, thereby inhibiting bone loss, suggesting that melatonin may be a potential target for osteoporosis. 77 Maria et al discovered that melatonin has osteoblast-inducing effects on human adipose-derived MSC. In vivo, 1-year nightly oral melatonin (15 mg/L) given to Her2/ neu female mice increased pErk1/2, pErk5, Runx2, osteoprotegerin, and receptor activator of NF-kB (RANK) ligand (RANKL) levels in bone. 78 Recent work by Xu et al 79 indicated that melatonin suppresses estrogen deficiency-induced osteoporosis and promotes osteoblastogenesis by inactivating the NLRP3 inflammasome. Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells, which may promote osteoblast differentiation and inhibit bone loss. 80 Moreover, melatonin enhances osteoblastic differentiation in vitro [81] [82] [83] [84] [85] [86] [87] [88] and promotes mouse cortical bone formation in vivo. 81 
| Melatonin inhibits osteolysis in osteoclasts
Melatonin also reduces the process of bone resorption to protect against osteoporosis. Ping et al examined the inhibitory effects of melatonin on the titanium particle-induced mouse model of calvarial osteolysis. They found that exogenous administration of melatonin significantly suppresses wear debris-induced bone resorption and the expression of inflammatory cytokines in vivo. RANKL, a transmembrane protein from the tumor necrosis factor (TNF) superfamily, is able to bind RANK on the surface of osteoclast precursors to trigger osteoclastogenesis. [89] [90] [91] [92] Chen et al 93 discovered
that RANKL signaling inhibits osteogenesis by promoting β-catenin degradation and inhibiting its synthesis, which further suppresses osteogenic differentiation of BMSC. Xiong et al found that soluble RANKL contributes to osteoclast formation in adult mice. Likewise, lack of soluble RANKL reduces osteoclast number and increases cancellous bone mass in adult mice. 94 Diabetic patients showed significantly higher mean levels of salivary RANKL and lower values of salivary osteoprotegrin and melatonin than healthy subjects. After melatonin treatment, there was a statistically significant decrease in the gingival index, pocket depth, and salivary levels of RANKL and a significant rise in salivary values of osteoprotegrin, indicating that melatonin has a favorable effect in slowing osteoclastogenesis, improving the quality of alveolar bone, and preventing the progression of periodontal disease. 95 Additionally, melatonin inhibits RANKL-induced osteoclast differentiation, F-actin ring formation, and osteoclastic resorption in a concentration-dependent manner in vitro. 96 Koyama et al 97 found that pharmacologic doses of melatonin elevates bone mass by suppressing resorption through downregulation of the RANKL-mediated formation and activation of osteoclasts. Kim et al 98 discovered that melatonin significantly suppresses RANKL-induced osteoclastogenesis, whereas the siRNA-mediated knockdown of the melatonin receptor fails to overcome the anti-osteoclastogenic effect. Pharmacological concentrations of melatonin (1-100 μmol/L) compared with physiological concentrations (0.01-10 nmol/L) significantly inhibit osteoclastogenesis of bone marrow monocytes via a ROS-mediated pathway instead of a SIRT1-independent pathway. 99 Taken together, these results strongly suggest that melatonin has significant potential for treating osteoporosis by facilitating osteogenesis and inhibiting osteolysis.
| Melatonin acts as a free radical scavenger against osteoporosis
As an antioxidant, 100 melatonin can affect bone metabolism by scavenging free radicals. Oxidative stress occurs when the production of free radicals exceeds the capacity of the antioxidant system. Reactive oxygen species (ROS) are believed to originate from random damage to DNA, lipids, proteins, and an increment in the concentration may induce a stress signal that activates specific redox-sensitive pathways and contributes to oxidative stress. 20 101 Yildirimturk et al 102 found that melatonin administration reduces oxidative stress-related biomarkers and shows beneficial effects on short-term bone formation and healing in streptozotocin (STZ)-induced diabetic rats. Moreover, melatonin treatment reduces total oxidant status/ total antioxidant status and oxidative stress index (OSI), which corresponds to improved hyperglycemia-induced oxidative stress and alveolar bone loss in diabetic rats with periodontitis. 103 Together, these results demonstrate that melatonin is a potential candidate against osteoporosis.
F I G U R E 2 Mechanisms of
melatonin on bone metabolism. This figure summarizes the roles of melatonin in diverse models, ranging from cells to animals and humans
| MELATONIN ACTS AS A PROTECTIVE AGENT AGAINST OSTEOPOROSIS
| Cell experiments
Accumulating studies demonstrate that melatonin has an antiosteoporosis role in cell models, 96, 104 animal models, 105, 106 and humans 73, 107 ( Figure 2 ). Tumor necrosis factor alpha (TNFα) plays a significant role in inflammation-related osteoporosis through the promotion of bone resorption and suppression of bone formation. Melatonin treatment was found to downregulate TNFα-induced SMAD ubiquitination regulatory factor 1 (SMURF1) expression and then decrease ubiquitination and degradation of SMAD1 protein, leading to steady bone morphogenetic protein (BMP)-SMAD1 signaling activity and restoration of TNFα-impaired osteogenesis. 55 Zhang et al encapsulated melatonin into poly-microspheres to create a sustained melatonin release system. The results documented that this system generates a microenvironment with a relatively stable concentration of melatonin for a period of time to support osteogenic differentiation of human MSC (hMSC), suggesting that melatonin has the potential to act as a bone growth stimulator against osteoporosis. 108 Zaminy et al 109 discovered that melatonin stimulates the osteogenic differentiation of bone MSC, whereas it has a negative effect on ADSC. Melatonin enhances ALP activity in differentiating hMSC via MT2 and the MEK/ERK1/2 signaling cascade. Hence, the decrease in plasma melatonin levels observed in humans during late adulthood may further enhance susceptibility to osteoporosis. 110 Additionally, melatonin significantly and dose-dependently facilitates the proliferation of normal human bone cells (HOB-M cells) and a human osteoblastic cell line (SV-HFO cells), with a maximal effect at 50 mmol/L, concomitant with increased levels of type I collagen and reduced levels of procollagen type I c-peptide (PICP). 
| Animal experiments
Melatonin also modulates bone metabolism in rats, chickens, and goldfish. Melatonin-based dietary supplements have been regarded as an anti-aging therapy for age-related bone loss. 112, 113 Pineal gland-specific deletion of Tph1 may lead to a drop in melatonin levels and low bone mass due to an isolated decrease in bone formation. Skeletal analysis of MT2-deficient mice shows low bone mass. 35 In ovariectomized female Wistar rats, reduced levels of melatonin correlate with decreased bone mass, concomitant with augmented levels of ALP and PICP, and decreased levels of cross-linked carboxyterminal telopeptide of type I collagen (ICTP), hydroxyproline, and total calcium. 114 Inducible nitric oxide synthase (iNOS) plays a critical role in the pathogenesis of osteoporosis. Ovariectomy accelerates iNOS expression and increases the number of apoptotic cells in the nucleus pulposus and epiphyseal cartilage, whereas a 4-week treatment with melatonin (10 mg/kg/d) reverses these effects. These data indicate that melatonin may exert strong protection against osteoporosis by inhibiting iNOS signaling. 115 Type 2 diabetes mellitus is often complicated by osteoporosis. There is accumulating evidence that melatonin has a beneficial role in the regulation and restoration of damaged autophagic processes. 116 Melatonin improves the bone microstructure in diabetic rat models and downregulates the level of autophagy, concomitant with reduced ERK levels. Melatonin also enhances osteogenesis and suppresses autophagy in osteoblasts cultured with high glucose levels (10 μmol/L was better than 1 mmol/L). This suggests that melatonin may lower the level of autophagy in osteoblasts and delay diabetes-induced osteoporosis by inhibiting the ERK signaling pathway. 117 Trabecular thickness, trabecular area, and cortical thickness in rats showed a remarkable decrease after ovariectomy. However, administration of melatonin improved these indices. 118 Ladizesky et al reported that melatonin treatment restrains bone remodeling after ovariectomy. This protective effect of melatonin requires adequate concentrations of estradiol, and melatonin augments estradiol's effects on bone in ovariectomized rats. 119 In addition to rodents, melatonin also has antiosteoporosis effects in sheep. Pinealectomy increases trabecular separation but decreases thickness, which contributes to low bone mineral density (BMD), bone loss, and osteoporosis. 120 Suzuki et al developed an in vitro assay using fish scales that contain osteoclasts, osteoblasts, and the bone matrix, all of which are similar to those found in mammalian membranous bone. They reported that the melatonin derivative bromomelatonin suppresses osteoblastic activities and bone formation, as indicated by reduced BMD of the femoral metaphysis. 121, 122 Pinealectomized chicken exhibited scoliotic curvature, reduced BMD, low weight, and short cervical vertebrae compared to controls, concomitant with decreased levels of melatonin. 123 These results reveal that melatonin is a strong antiosteoporosis agent in animals.
| Human studies
Several studies have demonstrated that melatonin has bone-protective effects in humans, similar to those seen in animals. St Hilaire et al 124 found that low levels of melatonin occur in premenopausal women, concomitant with increased bone resorption. Maria et al discovered that melatonin activates MT2 receptor and promotes osteoblastogenesis by inhibiting RANKL signaling. Analysis of daily logs from the study also demonstrated a significant improvement in mood and sleep quality in women receiving melatonin vs placebo. 78 Moreover, melatonin supplementation is well tolerated, improves postmenopausal physical symptoms, restores imbalances in bone remodeling to prevent bone loss, and elevates the quality of life in perimenopausal women. 125 One-year treatment with melatonin (1 mg/d) increased BMD at the femoral neck of postmenopausal women with osteopenia in a dose-dependent manner, while high-dose (3 mg) melatonin also increased BMD in the spine. 126 Elevated melatonin concentrations might have a protective effect against postmenopausal bone loss, which suggests that melatonin may be protective against postmenopausal osteoporosis 127 ( Table 1 , Figure 2 ). In conclusion, a meta-analysis is needed to provide comprehensive clinical evidence for orthopedists and basic researchers.
| PROSPECTS AND CONCLUSIONS
Combined treatment involving melatonin seems to have beneficial effects on osteoporosis. Erdem et al discovered that combined treatment of caffeic acid phenethyl ester (CAPE) and melatonin promotes the maturation of new bone in distraction osteogenesis (Figure 1 ). These effects are likely a result of a reduction in bone resorption due to inhibition of NF-κB and free oxygen radicals. 128 The combination of melatonin and laser irradiation (808 nm, 80 mW, GaAlAs diode) markedly increased the expression of osterix, which promotes the differentiation and mineralization of MC3T3-E1 cells under hypoxic conditions. 129 Additionally, the combination of melatonin, strontium (citrate), vitamin D3, and vitamin K2 induced osteoblastogenesis, increased BMD, Melatonin also promotes bone formation in some oral diseases, including periodontitis-related bone loss. Periodontitis is an inflammatory condition characterized by gingival inflammation and resorption of alveolar bone. 131, 132 Periodontitis was induced in adult rats by placing the ligature at molar subgingival regions. The results indicated that the RANKL/osteoprotegerin ratio, Toll-like receptor (TLR)4/MyD88 activity, and pro-inflammatory cytokine levels were imbalanced following periodontitis. However, in melatonin-pretreated rats, all of these parameters were successfully restored to nearly normal levels with the maximal dose (100 mg/kg), which suggests that melatonin may counteract periodontitis-induced destructive bone damage. 133 Melatonin treatment reduces serum levels of terminal C telopeptide of collagen Type I (CTX), RANKL, and osteoclast activity but increases bone ALP in an experimental periodontitis rat model. The results revealed that melatonin treatment significantly inhibits regional resorption of alveolar bone and contributes to periodontal healing in this experimental periodontitis rat model. 134 Moreover, several published reports indicate that melatonin stimulates bone formation. [135] [136] [137] [138] Notably, melatonin also plays a therapeutic role against osteoporosis-related diseases and rare osteopathia. Melatonin deficiency acts as a central mechanism in the pathogenesis of adolescent idiopathic scoliosis (AIS), a common orthopedic disorder of unknown etiology and pathogenesis. 139 AIS is characterized by a lateral curvature of the spine that is often associated with osteopenia. Pinealectomy refers to surgical ablation of the pineal gland. Dr Thillard created the first pinealectomy model in 1959 by removing the pineal gland, which contributed to postoperative spinal curvature in 65% of the operated chickens. 140 It was not until 1983 that Machida and Duboussett popularized this model by drawing a morphological correlation with AIS in patients. 141 In their study, young chicks developed a three-dimensional spinal deformity, consisting of lateral curvature with vertebral body rotation, 2 weeks after pinealectomy. Pinealectomy may result in a rapid and marked loss of cancellous bone volume and profoundly disrupts trabecular structure, with increases in dynamic formative parameters, such as mineralizing surface, mineralization apposition rate, and adjusted appositional rate in a chicken AIS model. 142 Micro-CT data revealed that pinealectomized chickens had a greater degree of generalized osteoporosis compared with controls. The number of osteoblasts was significantly decreased as a result of pineal loss, while the number of osteoclasts showed no significant difference among chickens. These results suggest that melatonin deficiency reduces osteoblast proliferation and leads to the development of osteoporosis. 143 Chen et al found that treatment with 50 nmol/L melatonin enhanced the mRNA expression levels of osteogenic marker genes, including ALP, osteopontin, osteocalcin, and RUNX2, in the normal control hMSC group compared with the untreated normal control. During chondrogenic differentiation, melatonin treatment increases quantitative glycosaminoglycan synthesis in normal control hMSC, which is significantly elevated on day 21 compared with untreated normal control cells. 144 Multiple sclerosis (MS) is a common autoimmune and neurodegenerative disease of the central nervous system. Serum levels of melatonin usually decrease in MS patients who are also at risk of osteoporosis. In an autoimmune encephalomyelitis (EAE) model, which mimics MS, decreases of 25-hydroxyvitamin D, calcium, and osteocalcin (OCN) in EAE mice were significantly reversed by melatonin. 145 Moreover, melatonin has therapeutic potential for bone regeneration. Studies have demonstrated that melatonin can elevate bone ALP levels, increase bone mass and promote mineralization, collagen type I synthesis, new bone growth, and osteointegration. 32 Together, these findings demonstrate that melatonin can be applied to the treatment of osteoporosis-related diseases. Herein, we proposed that melatonin is a potential drug candidate against osteoporosis. Based on the published studies, we: (a) introduced the basic functions of melatonin and the background of osteoporosis and bone metabolism; (b) described the specific mechanisms of melatonin in bone metabolism, especially in the regulation of osteoblasts and osteoclasts; (c) summarized the roles of melatonin against osteoporosis in cells, animals, and humans; (d) introduced the roles of melatonin in oral diseases and osteoporosis-related diseases; (e) highlighted research progress regarding the melatonin signaling network in osteoporosis.
Although several lines of evidence have clarified the underlying mechanisms of melatonin in osteoporosis, the development of successful treatments that include melatonin has not been instituted to date. Additional translational research and clinical trials are needed before melatonin can be routinely used to prevent osteoporosis. Further investigations may focus on: (a) identifying the relationship between melatonin concentrations and the progression of osteoporosis; (b) exploring the safety and efficacy of preventive use of melatonin in adults; (c) determining the unknown mechanisms of melatonin in regulating osteoporosis; (d) providing more evidence via large-scale randomized controlled trials (RCT), especially among Asians; (e) a Cochrane systematic review and meta-analysis of high quality are needed to provide high-level evidence. Taken together, this review presents an elaborate picture of melatonin in bone metabolism and indicates the potential of melatonin as a novel therapeutic for osteoporosis.
